MODERATOR
:
SPEAKER
(S):
Mikkael Sekeres, MD, MS, Associate Professor of Medicine, The Cleveland Clinic Taussig Cancer Institute
Support and Therapy for Myelodysplastic Syndromes
David Steensma, MD, Associate Professor of Medicine and Oncology, Mayo Clinic
Description
The myelodysplastic syndromes (MDS), considered a form of leaukemia, are diagnosed in over 10,000 people yearly in the United States. These diseases result in significant peripheral blood cytopenias, often necessitating transfusion of blood products. This session will review the pathobiology and epidemiology of these diseases; the impact of transfusion needs and appropriate use of erythropoiesis stimulating agents in this population; and appropriate use of iron chelation therapy in MDS patients.
-
Describe the impact of transfusion needs in patients with myelodysplastic syndromes.
-
Describe the optimal timing of and indiction for use of iron chemation therapy in patients with myelodysplastic syndromes.
-
Determine the appropriate timing of and indication for use of erythropoiesis stimulating agents and colony stimulating facotrs in patients with myelodsyplastic syndromes.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.